The Immunologic Basis for an Attenuated Immune Response to the Influenza Vaccine After Repeated Annual Vaccination

Influenza Clinical Trial

— FLU1  

Official title:

The Immunologic Basis for an Attenuated Immune Response to the Influenza Vaccine After Repeated Annual Vaccination

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02876159
• Other study ID #: IRB00090196
• Status: Completed
• Phase: Phase 4
• Start date: July 2016
• Est. completion date: December 1, 2016

Study information

• Verified date: December 2018
• Source: Emory University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a prospective pilot study designed to suggest differences in the immunologic response to the seasonal influenza vaccine in people with regular vaccination history compared to those vaccinated less regularly. Participants will receive one dose of the Food and Drug Administration (FDA) approved 2016-2017 seasonal influenza vaccine. Immune system data will be collected at standard time points. The duration of the study for each participant will be approximately 1 month.

Description:

This is a prospective pilot study in 20 males and non-pregnant females, 20 to 30 years old, inclusive, who are in good health and meet all eligibility criteria. The study is designed to evaluate differences in the immunologic response to the seasonal influenza vaccine in people with regular vaccination history compared to those vaccinated less regularly.

Participants will be sorted to either Arm A (Naïve) or Arm B (Experienced) based on their vaccination history. Those vaccinated no more than 2 out of the past 5 years will be in Arm A. Those vaccinated 3 or more out of the past 5 years will be in Arm B. Participants will receive one dose of the Food and Drug Administration (FDA) approved 2016-2017 seasonal influenza vaccine. The duration of the study for each participant will be approximately 1 month. Subjects will return for clinic visits on Days 3, 8, 15, and 29 during the month follow-up period following vaccination.

The study has two primary objectives; to evaluate the antibody response to the influenza vaccine in people who are vaccinated regularly and those vaccinated less regularly; the second is to evaluate circulating follicular helper T cells (TFH) in people who are vaccinated regularly and those vaccinated less regularly.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 20
• Est. completion date: December 1, 2016
• Est. primary completion date: October 18, 2016
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 20 Years to 30 Years

Eligibility

Inclusion Criteria:

• Capable of informed consent and provision of written informed consent before any study procedures.

• Capable of attending all study visits according to the study schedule.

• Are in good health, as determined by medical history and targeted physical exam related to this history.

• Oral temperature is less than 38 degrees Celsius.

• Resting pulse rate is between 50 and 115 beats per minute.

• Female subjects of childbearing age must have a negative urine pregnancy test within 24 hours before study vaccination.

• Have received the influenza vaccine at least 3 of the past 5 years or have received the influenza vaccine in 2 or less of the past 5 years.

Exclusion Criteria:

• Have an acute illness within 72 hours before vaccination.

• Have any condition that, in the opinion of the principal investigator, would place the subject at an unacceptable risk of injury or confound the interpretation of the study results.

• Have any acute or chronic medical condition that, in the opinion of the principal investigator, would make vaccination unsafe or interfere with the evaluation of immune response to study vaccination.

• Have a suppressed immune system as a result of illness, immunosuppressive medication, chemotherapy, or radiation therapy within 3 years prior to study vaccination.

• Have known HIV, hepatitis B, or hepatitis C infection.

• Have a known history of autoimmune disease.

• Have taken oral or parenteral corticosteroids of any dose within 30 days before study vaccination.

• Have taken high-dose inhaled corticosteroids within 30 days before study vaccination.

• Have received any licensed live vaccine within 30 days or any licensed inactivated vaccine within 14 days prior to study vaccination.

• Have planned vaccination with any vaccine during the 29-day duration of subject study participation.

• Have received immunoglobulin or other blood products, with the exception of Rho D immunoglobulin, within 90 days prior to study vaccination.

• Have donated blood or blood products within 30 days before study vaccination, plan to donate blood at any time during the 29-day duration of subject study participation, or plan to donate blood within 30 days after the last blood draw.

• Have known hypersensitivity or allergy to eggs, egg protein, chicken protein, or other compounds of the study vaccine.

• Have a history of severe reactions following vaccination with influenza virus vaccines

Related Conditions & MeSH terms

• Influenza
• Influenza, Human

Intervention

Biological:
• 2016-2017 Influenza Vaccine
Quadrivalent influenza A/Hemagglutinin Type 1 (H1N1), A/Influenza A virus subtype (A/H3N2) H3N2,and B virus vaccine for Intramuscular (IM) use is a sterile, clear and slightly opalescent suspension administered as a single 0.5 mL intramuscular dose.

Locations

Country	Name	City	State
United States	The Hope Clinic of the Emory Vaccine Center	Atlanta	Georgia

Sponsors (1)

Lead Sponsor	Collaborator
Emory University

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in Geometric Mean Serum Hemagglutination Inhibition (HAI) Antibody Titer	Geometric mean serum HAI antibody titers serum HAI titer will be collected via blood draw. Titer for serum HAI antibodies will be calculated using the geometric mean. Change is defined as the difference in means from Day 1 to Day 29.	Baseline (Day 1), Day 29
Primary	Change in Mean Level of Circulating Follicular Helper T (TFH) Cells	TFH cells will be collected via blood draw. Change is defined as the difference in the mean levels of cells from baseline, day 8, and day 15.	Up to 15 Days
Secondary	Change in Mean Levels of Plasmablasts	Plasmablasts will be collected via blood draw. Change is defined as the difference in mean levels from baseline to Day 29.	Up to 29 Days
Secondary	Change in Mean Levels of Memory B Cells From Baseline (Day 1) to Day 29	Memory B cells will be collected via blood draw. Change is defined as the difference in mean levels from baseline to Day 29.	Baseline (Day 1) and Day 29
Secondary	Change in Mean Levels of Antigen-specific IL-2 Producing CD4+ T Cells	Antigen-specific Interleukin 2 (IL-2) producing cluster of differentiation 4 (CD4)+ T cells will be collected via blood draw. Change is defined as the difference in mean levels from baseline to Day 29.	Up to 29 Days
Secondary	Change in Mean Levels of Antigen-specific Cluster of Differentiation 8 (CD8) + T Cells	CD8+T cells will be collected via blood draw. Change is defined as the difference in mean levels from baseline to Day 29.	Up to 29 Days